PDF(Pubmed)
Abstract：
Objectives: The purpose of the study was to comprehensively evaluate efficacy and safety of CDDP in patients with AMI undergoing PCI. Methods: A computerised search was conducted on the CNKI, WF, VIP, CBM, PubMed, Embase, Web of Science, and Cochrane Library databases for RCTs of CDDP adjuvant therapy for AMI up to May 2023. STATA 17.0 was used to perform meta-analyses, sensitivity analyses, subgroup analyses, meta-regression, and publication bias assessments. TSA 0.9.5.10 Beta was used for trial sequential analysis (TSA). Evidence confidence of meta results was evaluated by GRADE (Grading of Recommendations Assessment, Development and Evaluation) according to the instructions. Results: The results of the meta-analysis showed that CDDP combined with conventional western treatment (CWT) was superior to CWT in increasing LVEF and TCER and decreasing LVEDD, hs-CRP, IL-6 and TNF-α. The quality of evidence for TCER was moderate, LVEF, LVEDD, IL-6, and TNF-α were low. The TSA results showed that the total number of samples collected in this study met the requirements for meta-analysis and excluded the possibility of false positives, further confirming the efficacy of CDDP for the treatment of AMI undergoing PCI. Conclusion: Adjuvant treatment of AMI with CDDP has shown exciting and safe benefits in improving cardiac function and reducing inflammatory response in patients with AMI undergoing PCI, but the quality of some of the included studies was poor, and the results should be interpreted with caution until further confirmation by well-designed RCTs. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/#recordDetails], identifier [CRD42023453293].
摘要：
目的：本研究的目的是全面评估CDDP在接受PCI的AMI患者中的有效性和安全性。方法：在CNKI网站上进行计算机检索，WF,VIP,CBM,PubMed,Embase,WebofScience,和Cochrane库数据库，用于截至2023年5月CDDP辅助治疗AMI的RCT。STATA17.0用于进行荟萃分析，敏感性分析，亚组分析，元回归，和出版偏见评估。TSA0.9.5.10Beta用于试验序贯分析(TSA)。荟萃结果的证据可信度通过等级(建议评估的分级，开发和评估)根据说明。结果:meta分析结果显示,CDDP联合常规西医治疗(CWT)在提高LVEF和TCER、降低LVEDD方面优于CWT,hs-CRP,IL-6和TNF-α。TCER的证据质量适中，LVEF,LVEDD,IL-6和TNF-α水平较低。TSA结果显示,本研究收集的样本总数符合meta分析的要求,排除了假阳性的可能性,进一步证实CDDP用于PCI治疗AMI的疗效.结论：CDDP辅助治疗AMI在改善AMI患者PCI术后心功能和减轻炎症反应方面显示出令人兴奋和安全的益处，但部分纳入研究的质量较差。在精心设计的RCT进一步确认之前，应谨慎解释结果。系统审查注册：[https://www。crd.约克。AC.uk/PROSPERO/#recordDetails],标识符[CRD42023453293]。
